Medtronic plc

Medtronic plc

MDT
Medtronic plcUS flagNew York Stock Exchange
83.19
USD
+3.99
- -
106.49BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
16.97
18.49
20.45
21.55
22.08
22.7
21.57
22.39
23.6
23.48
24.38
26.09
- -
28.37
Basic EPS, GAAP
3.06
2.44
2.51
2.92
2.29
3.44
3.57
2.68
3.75
2.83
2.77
3.63
- -
3.75
Free Cash Flow per Basic Share
4.55
3.95
2.96
4.08
2.67
4.36
4.49
3.63
4.45
3.44
3.92
4.03
- -
4.23
Dividend per Share
1.11
1.22
1.52
1.72
1.84
2
2.16
2.32
2.52
2.72
2.76
2.79
- -
2.84
Book Value per Share
20
49.67
15.4
16.88
17.97
19.51
20.98
21.26
22.53
22.85
22.9
24.48
- -
25.46
Tangible Book Value per Share
6.55
-14.06
-11.59
-8.41
-7.7
-7.66
-5.99
-6.02
-2.51
-3.46
-2.86
-4
- -
-2.08
Basic Weighted Avg Shares
1,002
1,096
1,410
1,379
1,357
1,346
1,341
1,345
1,342
1,330
1,328
1,286
- -
1,282
Sales/Revenue/Turnover
17,005
20,261
28,833
29,710
29,953
30,557
28,913
30,117
31,686
31,227
32,364
33,537
36,364
36,363
Operating Margin (%)
28.33
22.49
20.67
20.15
20.14
21.7
18.06
16.25
18.65
18.67
17.06
19.5
18.78
18.77
Depreciation Expense
850
1,306
2,820
2,917
2,644
2,659
2,663
2,702
2,707
2,697
2,647
2,861
2,958
2,958
Net Income, GAAP
3,065
2,675
3,538
4,028
3,104
4,631
4,789
3,606
5,039
3,758
3,676
4,662
4,801
4,801
Effective Tax Rate (%)
17.27
23.26
18.4
12.56
45.46
10.53
- -
6.8
8.27
29.46
23.42
16.63
21.17
21.17
Profit Margin (%)
18.02
13.2
12.27
13.56
10.36
15.16
16.56
11.97
15.9
12.03
11.36
13.9
13.2
13.2
Working Capital
15,651
21,671
16,435
10,609
12,896
13,495
11,665
14,039
10,665
12,624
11,146
10,935
13,129
13,129
LT Debt
10,259
33,673
30,020
25,881
23,705
24,477
22,021
26,378
20,372
24,344
23,932
25,642
26,173
26,173
Total Equity
19,443
53,230
52,063
50,330
50,822
50,212
50,872
51,602
52,722
51,665
50,420
48,256
50,072
50,072
Return on Invested Capital (%)
13.14
5.75
5.6
6.24
4.07
7.74
- -
5.92
6.97
5.34
5.51
7.06
6.87
6.87
Return on Capital (%)
10.96
5.2
6.52
9.11
6.98
11.58
- -
8.21
10.07
7.64
7.59
9.05
8.77
8.78
Return on Common Equity (%)
15.64
7.19
9.3
17.91
13.03
18.29
17.61
12.71
17.13
12.39
12.09
15.07
14.98
14.98

Capital Structure

FRC

in mil. unless spec.
Oct'26
Jan'26
Apr'26
ST Debt
1,420
191
1,788
LT Borrowings
27,625
27,822
26,119
LT Finance Leases
55
58
54
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,282
1,283
1,280
Market Capitalization
116,284
132,008
103,797

Working Capital

FRC

in mil. unless spec.
Oct'26
Jan'26
Apr'26
Total Current Assets
23,996
24,071
24,787
Cash, Cash Equivalents & STI
8,327
8,383
9,220
Accounts Receivable, Net
6,389
6,359
6,643
Inventories
6,156
6,309
5,951
Total Current Liabilities
9,935
9,495
11,658
Payables & Accruals
6,384
6,723
7,192
ST Debt
1,420
191
1,788
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.36%
-0.55%
3.76%
Free Cash Flow
6.21%
3.38%
4.65%
Net Income, GAAP
6.07%
8.39%
2.98%
Sales/Revenue/Turnover
2.41%
3.89%
8.43%
Total Cash Common Dividend
5.53%
3.2%
1.39%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,702
7,984
8,089
8,589
32,364
2025
7,915
8,403
8,292
8,927
33,537
2026
8,578
8,961
9,017
9,807
36,364

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.59
0.68
0.99
0.49
2.77
2025
0.81
0.99
1.01
0.82
3.63
2026
0.81
1.07
0.89
0.97
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.69
0.69
0.69
0.69
2.76
2025
0.69
0.7
0.7
0.7
2.79
2026
0.71
0.71
0.71
0.71
- -

Company Description

APIChatGPT
CEO
Geoffrey Straub Martha
Full Time Employees
95,000
Sector
Healthcare
Industry
Medical - Devices
Address
Building Two, Parkmore Business Park West Galway United States of America 2
IPO Date
May 2, 1973
Business
Medtronic plc (NYSE: MDT) develops, manufactures, and markets a wide range of medical devices and therapies for the treatment of chronic diseases worldwide. The company offers products across four main segments: cardiovascular (including pacemakers, defibrillators, heart valves, and coronary stents under brands such as Evera, Protecta, and CoreValve); medical surgical (featuring surgical navigation systems, endoscopic tools, and stapling devices like Hugo RAS and Valiant NaviCore); neuroscience (encompassing spinal cord stimulators, deep brain stimulation systems, and intrathecal drug delivery pumps such as Incepta and SynchroMed II); and diabetes (primarily continuous glucose monitoring systems, insulin pumps, and related software through the MiniMed and Guardian brands). Medtronic provides services including patient management software, remote monitoring platforms, and clinical decision support tools to healthcare providers, hospitals, clinics, and patients globally. Founded in 1949 and headquartered in Dublin, Ireland, with principal executive offices in Minneapolis, Minnesota, USA, Medtronic operates in more than 150 countries, serving markets in North America, Europe, Asia-Pacific, Latin America, and the Middle East through direct sales forces, distributors, and subsidiaries. The company targets physicians, hospitals, ambulatory surgery centers, and home care settings, with a focus on minimally invasive therapies and digital health solutions. Key subsidiaries include Covidien (acquired in 2015 for surgical and patient monitoring products) and Intersect ENT (recently integrated for sinus implants). In the past 1-2 years, Medtronic has pursued strategic expansions including the FDA approval and U.S. launch of the Hugo robotic-assisted surgery (RAS) system in 2024 for soft tissue indications, building on its European CE Mark; a multi-year collaboration with NVIDIA announced in 2024 to advance AI-enabled therapies using Medtronic's Gigamon data platform; and the acquisition of Mazor Robotics in 2018 followed by ongoing enhancements to its spinal robotics portfolio with the Mazor X Stealth Edition. The company completed a $4.1 billion acquisition of Covidien assets integration and reported expansions in diabetes care via the Simplera Sync sensor FDA clearance in 2024. Medtronic also announced organizational realignments in 2025 to streamline its four operating units amid portfolio optimization efforts.

Company News

APIChatGPT
  • Why Is Medtronic (MDT) Up 1.5% Since Last Earnings Report?

  • Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know

  • Is Medtronic PLC (MDT) a Bargain After 3.3% Drop? GF Value Says Undervalued

  • GMED vs. MDT: Which Medical Stock Has More Upside Potential?

  • 2 High-Yield Dividend Stocks to Buy and Hold for a Decade

  • Is It Worth Investing in Medtronic (MDT) Based on Wall Street's Bullish Views?

  • This Undervalued Medical-Devices Stock Is Poised for a Rebound

  • Worried About a Market Crash? These 3 Dividend Stocks Could Help Reduce Your Risk

  • Is the Options Market Predicting a Spike in Medtronic Stock?

  • 3 Dividend Stocks to Hold for the Long Haul

  • Got $2,500? 1 Unstoppable Medical Juggernaut to Buy Hand Over Fist and Hold for the Next 20 Years

  • Dividend Announcements: May 30-June 5, 2026

  • Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care

  • Medtronic Bets on Ablation, Robotics, and Hypertension

  • Is Medtronic Stock a Buy at 14x Forward Earnings?

  • 5 Best Dividend Stocks to Own in Case the AI Trade Ends

  • As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play

  • Medtronic: A Dividend Aristocrat At A Steal Now

  • Why Medtronic Stock May Have Just Become the Best Buy in the Entire Healthcare Sector

  • Can Medtronic Finally Challenge Intuitive Surgical's Robotic Surgical Systems Dominance?